Jiyuan Zhang
About Jiyuan Zhang
Jiyuan Zhang is the Director at BeiGene in Shanghai, China, with over a decade of experience in biomedical research and drug discovery.
Current Role at BeiGene
Jiyuan Zhang currently serves as the Director at BeiGene in Shanghai, China. He has been with the company since March 2020, focusing on drug discovery particularly in the field of oncology. This role leverages his extensive experience in biomedical research and translational science.
Previous Roles at Novartis and Eli Lilly
Before joining BeiGene, Jiyuan Zhang worked at Novartis Institutes for BioMedical Research (NIBR) as an Investigator II from 2017 to 2020 in Shanghai. His work at NIBR involved significant translational science projects. Prior to this, he served as a Senior Scientist at Eli Lilly China from 2016 to 2017, also in Shanghai. These roles have enriched his experience in the pharmaceutical industry and drug discovery.
Academic and Industry Experience
Jiyuan Zhang has a robust background in both academic and industry settings. From 2011 to 2016, he was a Postdoctoral Fellow at Columbia University, where he conducted crucial research in biomedical science. His diverse experience spans across prestigious institutions in the United States and China, contributing to his comprehensive expertise in drug discovery.
Educational Background at Fudan University
Jiyuan Zhang holds a Doctor of Philosophy (Ph.D.) in Human/Medical Genetics from Fudan University, where he studied from 2005 to 2011. He also earned a Bachelor's degree in Biology, General from the same institution, graduating after four years of study from 2001 to 2005. His education has provided a solid foundation in genetics and biology, critical for his work in drug discovery and biomedical research.
Focus on Drug Discovery and Oncology
Jiyuan Zhang has a strong focus on drug discovery, particularly in the field of oncology. His work spans over a decade and involves significant contributions to translational science and biomedical research. This focus is consistent throughout his roles in academia and the pharmaceutical industry.